ArticleSurgery today2011
Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.
Article in Surgery today, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis.BMC cancer · 2016Pooled it
- FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials.Medical oncology (Northwood, London, England) · 2013Pooled it
- Trial
- Trial
- Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.Medical oncology (Northwood, London, England) · 2013Trial
- Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.British journal of cancer · 2013Trial
- Article
- Lower serum CA125 level, negative vascular invasion, and wild BRAF were strongly associated with better 2-year disease-free survival in patients with stage III colorectal cancer who received adjuvant chemotherapy.Cancer biomarkers : section A of Disease markers · 2018Article
- Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer.American journal of cancer research · 2017Article
- Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer.Molecular and clinical oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFluoropyrimidine-based chemotherapy plus bevacizumab (BV) is the standard treatment for metastatic colorectal cancer (mCRC). The aim of this study was to investigate the efficacy of BV plus FOLFIRI (5-fluorouracil, leucovorin, irinotecan) as second-line treatment in mCRC patients refractory to first-line oxaliplatin-based chemotherapy, and determine potential predictive factors affecting survival.
methodsThirty-four consecutive patients were included in this retrospective study. All patients received FOLFIRI plus 5 mg/kg BV until progression or unmanageable toxicity occurred. Clinical factors and KRAS status were evaluated as potential biomarkers of efficacy.
resultsThe overall response was 23.5%. The median progression-free survival (PFS) and time-to-treatment failure (TTF) were 248 and 221 days, respectively. The median overall survival (OS) was 651 days. A univariate analysis revealed that normal thrombin antithrombin complex, alkaline phosphatase, lactate dehydrogenase, and carbohydrate antigen 125 (CA125) levels at baseline were associated with better PFS, TTF, and OS. A multivariate analysis showed that only the CA125 level at baseline was an independent negative predictor of both PFS and OS. KRAS status was not identified as a predictor.
conclusionsThe results of this study suggest that FOLFIRI plus BV is a viable option in second-line treatment for mCRC refractory to first-line FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) alone, and indicate that CA125 might be a predictive biomarker for the outcome.
Indexed as
Identifiers
21773895What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.